Document is current
Any future updates will be listed below
-
Authors
Gudmundsdottir, Valborg
Pedersen, Helle Krogh
Mazzoni, Gianluca
Allin, Kristine H.
Artati, Anna
Beulens, Joline W.
Banasik, Karina
Brorsson, Caroline
Cederberg, Henna
Chabanova, Elizaveta
De Masi, Federico
Elders, Petra J.
Forgie, Ian
Giordano, Giuseppe N.
Grallert, Harald
Gupta, Ramneek
Haid, Mark
Hansen, Torben
Hansen, Tue H.
Hattersley, Andrew T.
Heggie, Alison
Hong, Mun-Gwan
Jones, Angus G.
Koivula, Robert
Kokkola, Tarja
Laakso, Markku
Løngreen, Peter
Mahajan, Anubha
Mari, Andrea
McDonald, Timothy J.
McEvoy, Donna
Musholt, Petra B.
Pavo, Imre
Prehn, Cornelia
Ruetten, Hartmut
Ridderstråle, Martin
Rutters, Femke
Sharma, Sapna
Slieker, Roderick C.
Syed, Ali
Tajes, Juan Fernandez
Thomas, Cecilia Engel
Thomsen, Henrik S.
Vangipurapu, Jagadish
Vestergaard, Henrik
Viñuela, Ana
Wesolowska-Andersen, Agata
Walker, Mark
Adamski, Jerzy
Schwenk, Jochen M.
McCarthy, Mark I.
Pearson, Ewan
Dermitzakis, Emmanouil
Franks, Paul W.
Pedersen, Oluf
Brunak, Søren https://orcid.org/0000-0003-0316-5866
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (n°115317)
- License Information
-
More Information
Article History
Received: 3 September 2020
Accepted: 11 November 2020
First Online: 1 December 2020
Ethics approval and consent to participate
: Approval for the study protocol was obtained from each of the regional research ethics review boards separately (Lund, Sweden: 20130312105459927, Copenhagen, Denmark: H-1-2012-166 and H-1-2012-100, Amsterdam, Netherlands: NL40099.029.12, Newcastle, Dundee and Exeter, UK: 12/NE/0132), and all participants provided written informed consent at enrolment. The research conformed to the ethical principles for medical research involving human participants outlined in the Declaration of Helsinki.
: Not applicable.
: H.R. is an employee and shareholder of Sanofi. R.G. is employed with Novo Nordisk. For M.I.M. the following applies: The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Advisory panels: Pfizer, NovoNordisk, Zoe Global. Honoraria: Merck, Pfizer, Novo Nordisk and Eli Lilly. Stock options: Zoe Global. Research funding: Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi-Aventis, Servier, Takeda. As of June 2019, M.I.M. is an employee of Genentech, and a holder of Roche stock. The remaining authors declare that they have no competing interests.
